Growth in pharmaceuticals has rarely been straightforward, and the data from 2025 makes that point with unusual precision. The Hackett Group's 2026 North American Working Capital Survey found that the pharmaceutical industry's cash conversion cycle reached 185.8 days in 2025, up from 168.7 days the year before, with days inventory outstanding climbing to 251.5 days as biologics-driven inventory build and GLP-1 manufacturing investment created working capital requirements that revenue and profitability growth alone could not offset. Pharmaceutical revenue grew 7.7% to approximately $480 billion in 2025, while net income rose 77.5%, a result that reflects the extraordinary commercial momentum behind specialty drugs and innovative biologics. The operational complexity those numbers reveal is not a sign that pharmaceutical growth is slowing. It is a sign that the products driving growth are more demanding to manufacture, distribute, and manage than the small-molecule drugs that defined the previous generation of pharmaceutical supply chains. For life sciences, which has built its manufacturing reputation precisely on the complex, high-value biological products now at the centre of global pharmaceutical demand, that complexity is an opportunity as much as a challenge.

The inventory dynamic Hackett identifies reflects the structural characteristics of biologics and GLP-1 manufacturing rather than operational inefficiency. Gene therapies, cell-based treatments, and recombinant protein biologics carry longer lead times, more demanding cold chain requirements, and more complex batch release processes than conventional pharmaceuticals. As Hackett's director of finance transformation Damon Rottermond noted, switching from traditional drugs to gene therapies requires companies to hold more inventory across longer production cycles. For Irish pharmaceutical manufacturing sites, which produce a disproportionate share of the world's top-selling biologics including Humira, Keytruda, Opdivo, and Xarelto, the working capital implications of this shift are already embedded in operational planning. Ireland's biopharma community has been manufacturing complex biologics at scale for over two decades, making it exceptionally well positioned to support the next generation of GLP-1 and advanced therapy manufacturing that is now driving global capital expenditure decisions.

The supply chain resilience dimension adds further strategic relevance for Irish pharmaceutical manufacturing. Hackett specifically cited the concentration of active pharmaceutical ingredients in Asia, particularly India and China, as a driver of rising inventory days, as companies build buffer stock to protect against supply disruption while simultaneously expanding domestic manufacturing capacity. Ireland's pharmaceutical manufacturing base offers precisely the kind of geographically diversified, regulatory-grade manufacturing alternative that global pharmaceutical companies are investing in to reduce their dependence on Asian API supply routes. Ireland exported €139 billion in pharmaceutical products in 2025, representing 53% of all Irish goods exports, with the country hosting more FDA-registered drug manufacturing sites per capita than any other European nation. That infrastructure, combined with Ireland's mature HPRA regulatory framework and its EU Mutual Recognition Agreement with the FDA, positions Irish sites as the natural beneficiaries of the supply chain diversification strategies that Hackett's working capital data suggests are already underway.

Three actions would allow Irish pharmaceutical companies and life sciences stakeholders to convert the working capital complexity Hackett identifies into a competitive modernisation opportunity. First, pharmaceutical manufacturing sites should invest in digital inventory management and demand sensing tools aligned to the specific batch release and cold chain characteristics of their biologics portfolios, using Enterprise Ireland's digitalisation funding programmes to accelerate the deployment of AI-enabled forecasting systems that reduce days inventory outstanding without compromising the buffer stock requirements that biologics supply chains genuinely require. Second, Irish pharmaceutical companies should engage proactively with global pharmaceutical partners seeking to diversify API and finished product manufacturing away from Asian supply routes, positioning Ireland's combination of EU regulatory standing, FDA inspection track record, and established biologics infrastructure as the most credible near-term alternative for high-value specialty drug manufacturing. Third, pharmaceutical leadership teams should work with NIBRT's advanced manufacturing research programmes to develop continuous manufacturing capabilities for GLP-1 and biologics production, reducing the batch cycle times and inventory holding requirements that are the primary drivers of the extended cash conversion cycles Hackett's survey documents, while simultaneously strengthening the operational excellence in pharma standards that differentiate Irish manufacturing sites in global capacity allocation decisions.

The GLP-1 and biologics boom is creating a more operationally demanding pharmaceutical supply chain, and the companies that modernise their working capital management, inventory strategy, and manufacturing infrastructure in response will be the ones best positioned to capture the growth that demand is generating. Ireland's pharmaceutical manufacturing sector has the infrastructure, the regulatory standing, and the workforce capability to lead that modernisation. The Hackett data confirms that the opportunity is substantial and the moment to act on it is now.